Relation between plasma trough concentration of Pazopanib and
progression free survival in metastatic soft tissue sarcoma patients
Marie-Sophie Minot-This1, Pascaline
Boudou-Rouquette1, Anne Jouinot1,3,
Sixtine de Percin1, David
Balakirouchenane2,4, Nihel
Khoudour2, Camille Tlemsani1,
Jonathan Chauvin5, Audrey
Thomas-Schoemann2,4, François
Goldwasser1,5, Benoit Blanchet2,4,
and Jérôme Alexandre1,6.
Affiliations:
1- Institut du Cancer Paris CARPEM, AP-HP, APHP.Centre, Department of
Medical Oncology, ARIANE, Cochin Hospital, Paris, France;
2 - Department of Pharmacokinetics and Pharmacochemistry, Cochin
Hospital, AP-HP, CARPEM, 75014, Paris, France
3 - INSERM U-1016, CNRS UMR-8104, F-75014, University of Paris, Institut
Cochin, Paris, France
4 – UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of
Paris, PRES Sorbonne Paris Cité, CARPEM 75006 Paris, France
5 – Lixoft, Antony, France
6 – Centre de Recherche des Cordeliers, Sorbonne Université, Université
de Paris, INSERM, Paris France.
Corresponding author: Pascaline Boudou-Rouquette, MD, AP-HP, Cochin
Hospital, Department of Medical Oncology, ARIANE program, Cancer
Research for PErsonalized Medicine (CARPEM), Paris, France
Tel: +33 1 58 41 23 30 ; Fax +33 1 58 41 14 34;pascaline.boudou@aphp.fr
Keywords (MeSH terms):
Pazopanib; pharmacokinetics; soft-tissue sarcoma; progression-free
survival; toxicity.